Phase 1RecruitingPriority 4 · Lower priorityNCT06793956
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
Plain-language summary
This trial is testing Sintilimab and Linperlisib Combination Treatment for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Sintilimab and Linperlisib Combination Treatment (DRUG): Sintilimab administered via intravenous infusion; Linperlisib administered orally.
Sintilimab and Linperlisib Combination Treatment
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details